Abstract | AIM: METHODS: RESULTS: No significant differences were noted in patient age, underlying disease, tumor location, Helicobacter pylori infection rate, or ESD-induced ulcer size between the 2 groups. At both 4 and 8 wk, the healing rates of ESD-induced ulcers were similar in the PPI-treated and the rebamipide-treated patients (4 wk: PPI, 27.2%; rebamipide, 33.3%; P = 0.5341; 8 wk: PPI, 90.9%; rebamipide, 93.3%; P = 0.6710). At 8 wk, the rates of granulation lesions following ulcer healing were significantly higher in the PPI-treated group (13.6%) than in the rebamipide-treated group (0.0%; P = 0.0103). Ulcer-related symptoms were similar in the 2 treatment groups at 8 wk. The medication cost of 8-wk treatment with the PPI was 10945 yen vs 4889 yen for rebamipide. No ulcer bleeding or complications due to the drugs were observed in either treatment group. CONCLUSION: The healing rate of ESD-induced ulcers was similar with rebamipide or PPI treatment; however, rebamipide treatment is more cost-effective and prevents granulation lesions following ulcer healing.
|
Authors | Masaki Takayama, Shigenaga Matsui, Masanori Kawasaki, Yutaka Asakuma, Toshiharu Sakurai, Hiroshi Kashida, Masatoshi Kudo |
Journal | World journal of gastroenterology
(World J Gastroenterol)
Vol. 19
Issue 34
Pg. 5706-12
(Sep 14 2013)
ISSN: 2219-2840 [Electronic] United States |
PMID | 24039365
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Quinolones
- Lansoprazole
- rebamipide
- Alanine
|
Topics |
- Adenocarcinoma
(surgery)
- Aged
- Alanine
(analogs & derivatives, therapeutic use)
- Anti-Ulcer Agents
(therapeutic use)
- Dissection
(adverse effects)
- Female
- Gastroscopy
(adverse effects)
- Humans
- Iatrogenic Disease
- Lansoprazole
(therapeutic use)
- Male
- Middle Aged
- Peptic Ulcer
(drug therapy, etiology)
- Prospective Studies
- Proton Pump Inhibitors
(therapeutic use)
- Quinolones
(therapeutic use)
- Stomach Neoplasms
(surgery)
|